Zobrazeno 1 - 3
of 3
pro vyhledávání: '"CTP 13"'
Autor:
Laixi Xue, K. van Bilsen, M. W. J. Schreurs, M. E. J. van Velthoven, T. O. Missotten, A. A. H. J. Thiadens, R. W. A. M. Kuijpers, P. van Biezen, V. A. S. H. Dalm, J. A. M. van Laar, M. A. W. Hermans, W. A. Dik, P. L. A. van Daele, P. M. van Hagen
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were intro
Externí odkaz:
https://doaj.org/article/e152d3e8b46f4c7a951758b552d87606
Autor:
Laixi Xue, K. van Bilsen, M. W. J. Schreurs, M. E. J. van Velthoven, T. O. Missotten, A. A. H. J. Thiadens, R. W. A. M. Kuijpers, P. van Biezen, V. A. S. H. Dalm, J. A. M. van Laar, M. A. W. Hermans, W. A. Dik, P. L. A. van Daele, P. M. van Hagen
Publikováno v:
Frontiers in Medicine, 7:418. Frontiers Media S.A.
Frontiers in Medicine, Vol 7 (2020)
Frontiers in Medicine
Frontiers in Medicine, Vol 7 (2020)
Frontiers in Medicine
Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were intro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba65c21bf17d25fa1100bf43e3827798
https://pure.eur.nl/en/publications/007aabaf-4fdc-4242-9563-c99a7f4f8ee5
https://pure.eur.nl/en/publications/007aabaf-4fdc-4242-9563-c99a7f4f8ee5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.